Frank Perabo

5.0k citations

71 papers · 1.5k indexed · h-index 23

Impact in

Cancer Research top 5%
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
Pulmonary and Respiratory Medicine top 5%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment

Papers in

Cancer Research 21
- Cancer, Lipids, and Metabolism 13
- Cancer Genomics and Diagnostics 6
Pulmonary and Respiratory Medicine 31
- Prostate Cancer Treatment and Research 29

Co-authors: Stefan C. Müller Peter Albers Jörg Ellinger Patrick J. Bastian Alexander von Ruecker Stefan C. Mueller Doris Schmidt Andreas Wirger
Journals: Journal of Clinical Oncology (17 papers)The Journal of Urology (7 papers)Annals of Oncology (5 papers)Urology (3 papers)Investigational New Drugs (2 papers)
Partner nations: Germany United States Belgium

In The Last Decade

Frank Perabo

70 papers receiving 1.5k citations

Peers

Countries citing papers authored by Frank Perabo

Since Specialization

Citations

This map shows the geographic impact of Frank Perabo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Perabo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Perabo more than expected).

Fields of papers citing papers by Frank Perabo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Perabo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Perabo. The network helps show where Frank Perabo may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Frank Perabo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frank Perabo Line = papers co-authored together Frank Perabo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors The Oncologist ·Apostolia M. Tsimberidou, Farshid Dayyani, David Sommerhalder, 梁姚姚, Soroka Baker, Jason T. Henry, Cesar A. Perez, Abhijit Chakraborty, Mehmet A. Baysal, Chandtip Chandhasin, L. Turnbull, Kenneth Oja, Ivan King, Frank Perabo	2025	0
2	Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Arun Azad, Craig Underhill, Howard Gurney, Lisa G. Horvath, Mark Voskoboynik, Sajan Mahamud Alvee, L. Turnbull, Ivan King, Frank Perabo, Guangyu Guo	2024	1
3	Inhibitoren des Androgenrezeptor-N-Terminus’ Der Urologe ·Marie C. Hupe, Anne Offermann, Frank Perabo, Olga A. Makurina, Sven Perner, Axel S. Merseburger, Marcus V. Cronauer	2017	6
4	EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy Annals of Oncology ·Ulka N. Vaishampayan, Bruce Montgomery, Michael S. Gordon, David C. Smith, Zhihong Jiang, J. F. Banfield, Matheus Noronha Alberti, Olga A. Makurina, Frank Perabo, K.N. Chi	2017	2
5	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer European Urology ·Christopher P. Evans, Celestia S. Higano, Thomas E. Keane, Gerald L. Andriole, Fred Saad, Peter Iversen, Kurt Miller, Choung‐Soo Kim, Go Kimura, Andrew J. Armstrong, Cora N. Sternberg, Yohann Loriot, Johann S. de Bono, Sarah B. Noonberg, Hank Mansbach, Suman Bhattacharya, Frank Perabo, Tomasz M. Beer, Bertrand Tombal	2016	66
6	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial The Lancet Oncology ·Yohann Loriot, Kurt Miller, Cora N. Sternberg, Karim Fizazi, Johann S. de Bono, Simon Chowdhury, Celestia S. Higano, Sarah B. Noonberg, Stefan Holmström, Harry H. Mansbach, Frank Perabo, De Phung, Cristina Ivanescu, Konstantina Skaltsa, Tomasz M. Beer, Bertrand Tombal	2015	140
7	Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study The Lancet Oncology ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiří Heráček, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Mohammad Hirmand, Matthew R. Smith	2014	71
8	Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. Journal of Clinical Oncology ·Michael J. Morris, Yohann Loriot, Tomasz M. Beer, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann S. de Bono, Bertrand Tombal, Sarah B. Noonberg, Harry H. Mansbach, Suman Bhattacharya, Frank Perabo, De Phung, Dana E. Rathkopf	2014	2
9	Antiproliferative and apoptosis inducing effects of indirubin-3′-monoxime in renal cell cancer cells Urologic Oncology Seminars and Original Investigations ·Frank Perabo, Vavia Pradeep, احمد الهیاری, Doris Schmidt, Stefan C. Mueller	2009	25
10	Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: A prognostic entity Cancer Letters ·Jörg Ellinger, Patrick J. Bastian, Jialuo Bu, Philip Kahl, Frank Perabo, Reinhard Büttner, Stefan C. Müller, Alexander von Ruecker	2008	57
11	Soy isoflavone genistein in prevention and treatment of prostate cancer Prostate Cancer and Prostatic Diseases ·Frank Perabo, Đỗ Thị Hồng Xuyến, Jörg Ellinger, Alexander von Rücker, Stefan C. Müller, Patrick J. Bastian	2007	101
12	Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer. PubMed ·Frank Perabo, احمد الهیاری, Vavia Pradeep, Doris Schmidt, Alexander von Rücker, Andreas Wirger, Stefan C. Müller	2006	36
13	New agents for treatment of advanced transitional cell carcinoma Annals of Oncology ·Frank Perabo, Stefan C. Müller	2006	21
14	Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. PubMed ·Andreas Wirger, Frank Perabo, Naotatsu Otsuji, 杨甫传, Doris Schmidt, Christian Doehn, Stefan C. Mueller, D. Jocham	2005	32
15	Preclinical evaluation of superantigen (staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer International Journal of Cancer ·Frank Perabo, A. Chaouat, Andreas Wirger, Doris Schmidt, Eva Wardelmann, Khanh An Vo, Alexander von Ruecker, Stefan C. Mueller	2005	30
16	Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life Oncology Research and Treatment ·Peter Albers, Roswitha Siener, Michael Haertlein, Mohammad Javad Fallahi, Mazal Carmiel-Kostan, Frank Perabo, G Steiner, J. Blatter, Stefan C. Mueller	2002	69
17	Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation British Journal of Cancer ·Frank Perabo, Bente Heggem Kojan, Doris Schmidt, Heike Lindner, G Steiner, Roland Mattes, Andreas Wirger, K. Syragakid, Peter Albers, Elise C. Kohn, Alexander von Ruecker, Stefan C. Mueller	2001	29
18	Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo Urologic Oncology Seminars and Original Investigations ·Frank Perabo, Roland Mattes, Andreas Wirger, Gabriel Steiner, Bente Heggem Kojan, Doris Schmidt, K. Syragakid, Alexander von Ruecker, Stefan C. Müller	2001	20
19	Adjuvant chemotherapy in stage I and stage II testicular cancer World Journal of Urology ·Peter Albers, Frank Perabo, D. Melchior, Roswitha Siener	2001	10
20	[The incidence of Cooley's anemia in Burma]. PubMed ·Frank Perabo	1954	2

About Frank Perabo

Frank Perabo is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Oncology, Urology and Radiology, Nuclear Medicine and Imaging, having authored 71 papers that have together received 1.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (29 papers), Bladder and Urothelial Cancer Treatments (13 papers), Cancer, Lipids, and Metabolism (13 papers), Radiopharmaceutical Chemistry and Applications (12 papers), Epigenetics and DNA Methylation (11 papers), Cancer Treatment and Pharmacology (7 papers), Hormonal and reproductive studies (6 papers) and Cancer Genomics and Diagnostics (6 papers). The work is most often cited by research in Cancer Research (385 citations), Pulmonary and Respiratory Medicine (638 citations), Urology (92 citations), Drug Discovery (2 citations) and Oncology (308 citations). Frank Perabo has collaborated with scholars based in Germany, United States and Belgium. Frequent co-authors include Stefan C. Müller, Peter Albers, Jörg Ellinger, Patrick J. Bastian, Alexander von Ruecker, Stefan C. Mueller, Doris Schmidt, Andreas Wirger, Alexander von Rücker and Bertrand Tombal. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Urology, Annals of Oncology, Urology and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact